Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Teva
UBS
US Department of Justice
Queensland Health

Generated: August 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,252,535

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,252,535
Title:RNA interference tags
Abstract: The invention relates to a method for inhibiting the expression of a target gene in a eukaryotic cell. The method includes the following steps: a) providing at least one eukaryotic cell, the cell being capable of RNA interference, b) transfecting the eukaryotic cell with a composition that includes a genetic construct that includes an siRNA tag, and a target gene that forms a transcription unit together with the siRNA tag, and c) introducing at least one siRNA that is complementary to the siRNA tag of the transfected genetic construct to inhibit the expression of the target gene.
Inventor(s): Biekle; Wolfgang (Cologne, DE), Hahn; Peter (Kurten, DE)
Assignee: Qiagen GmbH (Hilden, DE)
Application Number:12/529,465
Patent Claims:1. A method for inhibiting the expression of a target gene in at least one eukaryotic cell capable of RNA interference, the method comprising: a) providing the at least one eukaryotic cell, b) transfecting the at least one eukaryotic cell with a composition comprising a genetic construct comprising the target gene, and an siRNA tag that forms a transcription unit together with the target gene, and c) introducing at least one siRNA which interacts with the siRNA tag of the transfected genetic construct to inhibit the expression of the target gene in the at least one eukaryotic cell, wherein the siRNA tag is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

2. The method as claimed in claim 1, wherein the at least one eukaryotic cell is in the form of a lysate.

3. The method as claimed in claim 1, wherein the siRNA is introduced into the at least one eukaryotic cell by means of a nucleic acid which codes for the siRNA, and wherein synthesis of the siRNA is under the control of a promoter.

4. The method as claimed in claim 3, wherein the promoter is under the control of an effector.

5. The method as claimed in claim 4, wherein the effector is transiently applied in order to bring about time-controlled synthesis of the siRNA.

6. The method as claimed in claim 1, wherein the siRNA comprises a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

7. The method as claimed in claim 1 further comprising controlling inhibition of the target gene in a plurality of eukaryotic cells by sequential introduction of the siRNA.

8. The method as claimed in claim 1, wherein the composition is used for transient generation of different expression patterns in the at least one eukaryotic cell or in a plurality of eukaryotic cells.

9. The method as claimed in claim 1, wherein the expression of the target gene is reduced by at least 40%.

10. The method as claimed in claim 9, wherein the expression of the target gene is reduced by at least 70%.

11. The method as claimed in claim 10, wherein the expression of the target gene is reduced by at least 90%.

12. The method as claimed in claim 1, wherein the degree of inhibition of the expression of the target gene is determined by means of quantifying the signal of a fused marker gene.

13. The method as claimed in claim 1, wherein the transfection of the at least one eukaryotic cell takes place transiently.

14. The method as claimed in claim 1, wherein the at least one eukaryotic cell is stably transfected.

15. A method for inhibiting the expression of at least one target gene in a eukaryotic cell, the method comprising: transfecting the eukaryotic cell with a composition comprising a first genetic construct comprising a first target gene, and a first siRNA tag that forms a transcription unit together with the first target gene; and a second genetic construct comprising the first target gene or a second target gene: and a second siRNA tag that forms a transcription unit together with the first target gene or the second target gene; and introducing at least one of an siRNA which interacts with the first siRNA tag of the transfected first genetic construct to inhibit the expression of the first target gene, and an siRNA which interacts with the second siRNA tag of the transfected second genetic construct to inhibit the expression of the first target gene or the second target gene, wherein the first siRNA tag and the second siRNA tag are each selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and wherein the first siRNA tag and the second siRNA tag differ in nucleic acid sequence.

16. The method as claimed in claim 15, wherein the first target gene and the second target gene differ in nucleic acid sequence.

17. The method as claimed in claim 15, wherein the first target gene represents a first allele and the second target gene represents a second allele of the same gene.

18. The method as claimed in claim 15, wherein the composition comprises a third genetic construct, wherein the third genetic construct comprises: the first target gene, the second target gene or a third target gene: and a third siRNA tag that forms a transcription unit together with the first target gene, the second target gene or the third target gene; and wherein the method further comprises introducing at least one of an siRNA which interacts with the first siRNA tag of the transfected first genetic construct to inhibit the expression of the first target gene, an siRNA which interacts with the second siRNA tag of the transfected second genetic construct to inhibit the expression of the first target gene or the second target gene, and an siRNA which interacts with the third siRNA tag of the transfected third genetic construct to inhibit the expression of the first target gene, the second target gene or the third target gene, wherein the third siRNA tag is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and wherein the third siRNA tag differs in nucleic acid sequence from the first siRNA tag and the second siRNA tag.

19. The method as claimed in claim 15, wherein at least one of the target genes is fused to a marker gene which makes it possible to detect the expression of a fusion protein expressed by the fused gene.

20. The method as claimed in claim 15, wherein both of the target genes are fused to a marker gene which makes it possible to detect the expression of fusion proteins expressed by the fused genes.

21. The method as claimed in claim 19, wherein the marker gene is selected from the group consisting of GFP, EGFP, YFP, CFP, dsRed, Myc tag, E tag, FLAG tag, Glu-Glu tag, GST tag, HA tag, His tag, HSV tag, luciferase, MBP, protein C tag, S tag, T7 tag, V5 tag, VSV-g tag, avidin/streptavidin/strep tag, thioredoxin, His-patch thioredoxin, .beta.-galactosidase, chloramphenicol acetyltransferase, cellulose binding domains (CBDs), chitin binding domain, staphylococcal protein A, streptococcal protein G, neo, hyg, pac, zeo, gpt, ble, dhfr, hpt and npt II.

22. The method as claimed in claim 19, wherein the marker gene codes for a fluorescence-generating protein.

23. The method as claimed in claim 1, wherein the at least one eukaryotic cell is of animal origin.

24. The method as claimed in claim 23, wherein the at least one eukaryotic cell is a mammalian cell.

25. The method as claimed in claim 1, wherein the at least one eukaryotic cell is of vegetable origin.

26. The method as claimed in claim 1, wherein the at least one eukaryotic cell is of mycotic origin.

27. The method as claimed in claim 26, wherein the at least one eukaryotic cell is a yeast cell capable of RNA interference.

28. The method as claimed in claim 15, wherein the eukaryotic cell is in the form of a lysate.

29. The method as claimed in claim 1, wherein the siRNA tag is a constituent of a promoter, enhancer or silencer.

30. The method as claimed in claim 1, wherein the siRNA tag is located downstream or upstream of the target gene or overlaps with the target gene.

31. The method as claimed in claim 1, wherein the siRNA tag is located in an intron of the target gene or overlaps with an intron.

32. The method as claimed in claim 1, wherein the genetic construct includes a protein tag fused to the target gene for protein purification.

33. The method as claimed in claim 32, wherein the protein tag for protein purification is selected from the group consisting of His tag, HA tag, ERK tag, GFP and related fusion tags, Myc tag, FLAG tag, GST tag, Strep tag, .beta.-Gal tag and MBP tag.

34. The method as claimed in claim 1, wherein the genetic construct is located on a vector.

35. The method as claimed in claim 15, wherein the first genetic construct and the second genetic construct are located on two different vectors.

36. The method as claimed in claim 15, wherein the first genetic construct and the second genetic construct are located on one vector.

37. The method as claimed in claim 34, wherein the vector is a plasmid.

38. The method as claimed in claim 34, wherein the vector is a transposon.

39. The method as claimed in claim 34, wherein the vector is a virus.

40. The method as claimed in claim 1, wherein the genetic construct is a constituent of a PCR product.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledApril 10, 2007PCT Application Number:PCT/EP2007/053459
PCT Publication Date:October 16, 2008PCT Publication Number:WO2008/122314

Details for Patent 8,252,535

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial Qiagen GmbH (Hilden, DE) 2037-11-08 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial Qiagen GmbH (Hilden, DE) 2037-11-08 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial Qiagen GmbH (Hilden, DE) 2037-11-08 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chubb
Daiichi Sankyo
Moodys
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.